Q3 2025 Management View CEO Frank Bedu-Addo provided an update on advancing PDS0101 (Versamune HPV) in HPV16-positive recurrent and/or metastatic head and neck cancer, highlighting the completion of ...

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction ...

Trodelvy did not meet the primary endpoint of progression-free survival in the ASCENT-07 trial for HR-positive, HER2-negative ...

Novartis (NVS) (OTCPK:NVSEF) has announced that its next-generation malaria treatment, KLU156 (GanLum), developed with Swiss ...

The trial showed that 63% of patients achieved a complete response (CR) at any time after receiving detalimogene coraplasmid.

Trodelvy didn't improve progression-free survival versus chemo in the post-endocrine therapy first-line HR-positive, HER2-negative advanced breast cancer setting.

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

Detalimogene voraplasmid (detalimogene; formerly EG-70) demonstrated promising responses in patients with high-risk Bacillus ...

CARDIAMP CMI Cohort Results -- In the open-label rolling cohort (n=5), patients saw an average 80-second increase in exercise ...

A year of escalating social-engineering attacks has produced one of the most efficient infection chains observed to date. Known as ClickFix, this method requires only that ...

AuthX partners with IGEL to strengthen endpoint security and streamline workforce access through faster, secure, passwordless authentication across virtual and shared environments. GAITHERSBURG, MD / ...

WASHINGTON -- An investigational dual therapy appeared to show antiviral activity in patients with chronic hepatitis D virus (HDV) infection, according to the phase II SOLSTICE trial.